0.00
100.00%
-228.74
Seagen Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $228.8 pivot point. If it approaches the $228.4 support level, significant changes may occur.
Seagen Inc Stock (SGEN) Financials Data
Seagen Inc (SGEN) Revenue 2023
SGEN reported a revenue (TTM) of $2.30 billion for the quarter ending September 30, 2023, a +23.40% rise year-over-year.
Seagen Inc (SGEN) Net Income 2023
SGEN net income (TTM) was -$750.23 million for the quarter ending September 30, 2023, a -17.82% decrease year-over-year.
Seagen Inc (SGEN) Cash Flow 2023
SGEN recorded a free cash flow (TTM) of -$701.21 million for the quarter ending September 30, 2023, a +2.52% increase year-over-year.
Seagen Inc (SGEN) Earnings per Share 2023
SGEN earnings per share (TTM) was -$4.01 for the quarter ending September 30, 2023, a -16.23% decline year-over-year.
Seagen Inc Stock (SGEN) Latest News
Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast
Benzinga
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
Zacks Investment Research
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
The Motley Fool
Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'
Benzinga
Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune
Benzinga
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
Zacks Investment Research
About Seagen Inc
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Cap:
|
Volume (24h):